•
Mar 31, 2020

Interactive Brokers Q1 2020 Earnings Report

Interactive Brokers reported diluted earnings per share of $0.60 and adjusted diluted earnings per share of $0.69.

Key Takeaways

Interactive Brokers Group reported a decrease in net revenues to $532 million, but an increase in commission revenue driven by higher customer trading volume amid market volatility. The company's strategic investments and currency diversification strategy impacted other income, while customer bad debt expense decreased.

Commission revenue increased 55% due to higher customer trading volume.

Net interest income increased 4% due to higher customer credit and margin loan balances.

Other income decreased due to losses from strategic investments and currency diversification.

Customer bad debt expense decreased due to lower expenses from volatile markets.

Total Revenue
$532M
Previous year: $558M
-4.7%
EPS
$0.69
Previous year: $0.64
+7.8%
Customer Accounts
760K
Previous year: 623K
+22.0%
Customer Equity
$161B
Previous year: $148B
+8.9%
DARTs
1.45M
Previous year: 848K
+71.0%
Gross Profit
$581M
Previous year: $577M
+0.7%
Cash and Equivalents
$3.1B
Previous year: $2.55B
+21.8%
Total Assets
$75.8B
Previous year: $63.5B
+19.4%

Interactive Brokers

Interactive Brokers

Forward Guidance

The impact of the COVID-19 pandemic on the Company’s future financial results could be significant but currently cannot be quantified, as it will depend on numerous evolving factors that currently cannot be accurately predicted.

Positive Outlook

  • The Company is committed to ensuring the highest levels of service to its customers.
  • The Company’s technical infrastructure has withstood the challenges presented by the extraordinary volatility and increased market volume.
  • The Company can run its business from alternate office locations and/or remotely if a Company office must temporarily close due to the spread of the COVID-19 pandemic.
  • The Company committed $5 million to assist efforts to provide food and support for people affected by the COVID-19 pandemic in the United States as well as to advance medical solutions.